• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum levels of carbohydrate antigenic determinant (CA 19.9) in obstructive jaundice.

作者信息

Benamouzig R, Buffet C, Fourre C, Ink O, Moati F, Etienne J P

出版信息

Dig Dis Sci. 1989 Oct;34(10):1640-2. doi: 10.1007/BF01537129.

DOI:10.1007/BF01537129
PMID:2791822
Abstract
摘要

相似文献

1
Serum levels of carbohydrate antigenic determinant (CA 19.9) in obstructive jaundice.梗阻性黄疸患者血清中糖类抗原决定簇（CA 19.9）水平
Dig Dis Sci. 1989 Oct;34(10):1640-2. doi: 10.1007/BF01537129.
2
Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.血清肿瘤标志物癌胚抗原（CEA）、糖类抗原50（CA 50）和糖类抗原242（CA 242）在鉴别引起黄疸和胆汁淤积的恶性与良性疾病中的临床价值；一项前瞻性研究的结果
Anticancer Res. 1992 Sep-Oct;12(5):1687-93.
3
The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Scand J Gastroenterol. 1993 Nov;28(11):981-7. doi: 10.3109/00365529309098296.
4
[Serum bilirubin and alkaline phosphatase levels before and after biliary drainage in obstructive jaundice].[梗阻性黄疸患者胆汁引流前后血清胆红素及碱性磷酸酶水平]
Gaoxiong Yi Xue Ke Xue Za Zhi. 1986 Aug;2(8):495-501.
5
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.评估CA 19-9作为胰腺癌血清肿瘤标志物的价值。
Br J Cancer. 1986 Feb;53(2):197-202. doi: 10.1038/bjc.1986.35.
6
CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.非肿瘤性肝病中的糖类抗原19-9。一项临床与实验室研究。
Clin Chim Acta. 1992 Sep 15;210(1-2):145-51. doi: 10.1016/0009-8981(92)90053-s.
7
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.六种血清肿瘤标志物（癌胚抗原、糖类抗原50、糖类抗原242、组织多肽抗原、组织多肽特异性抗原、组织激肽释放酶抑制因子）及常规实验室检查在肝胰胆恶性肿瘤诊断中的多变量分析
Anticancer Res. 1995 Nov-Dec;15(6B):2731-7.
8
Studies on the activity of so-called excretory enzymes in experimental obstructive jaundice in rabbits. II. Serum alkaline phosphatase (alkp), leucine aminopeptidase (lap) and gamma-glutamyl transpeptidase (ggtp) activities.家兔实验性梗阻性黄疸中所谓排泄酶活性的研究。II. 血清碱性磷酸酶（ALKP）、亮氨酸氨肽酶（LAP）和γ-谷氨酰转肽酶（GGTP）活性
Acta Med Pol. 1968;9(1):87-93.
9
[CA 19-9 and CA 125 in hepatobiliary pathology].[肝胆病理学中的CA 19-9和CA 125]
Acta Gastroenterol Belg. 1987 Jan-Feb;50(1):45-51.
10
Study of the abnormal lipoprotein-X in obstructive and non-obstructive jaundice.阻塞性和非阻塞性黄疸中异常脂蛋白-X的研究。
Clin Chim Acta. 1973 Oct 30;48(3):243-8. doi: 10.1016/0009-8981(73)90192-7.

引用本文的文献

1
Fluorescent contrast agents for tumor surgery.用于肿瘤手术的荧光造影剂。
Exp Ther Med. 2018 Sep;16(3):1577-1585. doi: 10.3892/etm.2018.6401. Epub 2018 Jul 4.
2
Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.良性肝胆疾病中糖类抗原19.9的升高及其与血清胆红素浓度的相关性。
Dig Dis Sci. 2008 Dec;53(12):3213-7. doi: 10.1007/s10620-008-0289-8. Epub 2008 May 9.
3
Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.

本文引用的文献

1
Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.利用美国国立癌症研究所血清库对CA 19-9免疫放射分析进行的初步临床评估。
Int J Cancer. 1984 Mar 15;33(3):339-45. doi: 10.1002/ijc.2910330310.
2
Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.上消化道疾病患者中新型肿瘤标志物CA 19-9与甲胎蛋白和癌胚抗原的比较
J Clin Pathol. 1984 Feb;37(2):218-22. doi: 10.1136/jcp.37.2.218.
3
Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers.
遗传性血色素沉着症患者血清中糖类抗原19.9升高及肝脏中过表达
Gut. 1994 Aug;35(8):1107-11. doi: 10.1136/gut.35.8.1107.
Jpn J Med. 1985 May;24(2):121-30. doi: 10.2169/internalmedicine1962.24.121.
4
CA 19-9 and pancreatic adenocarcinoma.糖类抗原19-9与胰腺腺癌
Cancer. 1986 Feb 15;57(4):779-83. doi: 10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c.
5
Elevated serum levels of tumor marker CA19-9 in acute cholangitis.
Dig Dis Sci. 1988 Oct;33(10):1223-5. doi: 10.1007/BF01536670.
6
CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.良性和恶性胰腺及胆道疾病中的糖类抗原19-9和糖类抗原50
Cancer. 1988 May 15;61(10):2100-8. doi: 10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z.
7
Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Digestion. 1985;31(2-3):67-76. doi: 10.1159/000199182.